When cardiomyopathy, cancer, and COVID‐19 collide: A case report | Zendy

Symonds Lynn | Zendy; Natarajan Poorna | Zendy; Cheng Richard K. | Zendy; Lam Diana L. | Zendy; Kilgore Mark | Zendy; Kim Janice | Zendy; Calhoun Kristine | Zendy; Minami Elina | Zendy; Gralow Julie R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

When cardiomyopathy, cancer, and COVID‐19 collide: A case report

Author(s) -

Symonds Lynn,

Natarajan Poorna,

Cheng Richard K.,

Lam Diana L.,

Kilgore Mark,

Kim Janice,

Calhoun Kristine,

Minami Elina,

Gralow Julie R.

Publication year - 2021

Publication title -

the breast journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.533

H-Index - 72

eISSN - 1524-4741

pISSN - 1075-122X

DOI - 10.1111/tbj.14182

Subject(s) - medicine , malignancy , breast cancer , lumpectomy , cancer , heart transplantation , covid-19 , intensive care medicine , cardiomyopathy , oncology , heart failure , mastectomy , disease , infectious disease (medical specialty)

Malignancy has historically prohibited solid organ transplant; however, patients with effectively treated, favorable‐risk cancers should not necessarily be eliminated as transplant candidates. These cases require careful review by a multidisciplinary team. Here, we report the case of a woman with end‐stage heart failure undergoing heart transplant evaluation during the COVID pandemic who was found to have early‐stage, hormone receptor‐positive breast cancer. Given her favorable cancer‐related prognosis, a multidisciplinary committee recommended lumpectomy, accelerated partial breast irradiation, and adjuvant aromatase inhibitor therapy for definitive treatment to allow for consideration of orthotopic heart transplant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research